Retatrutide vs Tirzepatide: What the Research Literature Can and Cannot Say
Retatrutide vs tirzepatide is one of the most obvious comparison questions in current peptide research, but it is also one of the easiest to mishandle. The reason is simple: retatrutide and tirzepatide differ mechanistically, and their published datasets invite comparison, but the literature still lacks direct head-to-head trials that would support strong ranking claims. That means a responsible comparison article should focus on mechanism and evidence limits rather than pretending the answer is already settled. The Core Mechanistic Difference Tirzepatide is a dual agonist at GIP and GLP-1 receptors. Retatrutide adds a third receptor pathway: glucagon. That extra GCGR component … Continue reading